UroGen Pharma Ltd (NAS:URGN)
$ 13.05 -0.76 (-5.5%) Market Cap: 549.59 Mil Enterprise Value: 437.91 Mil PE Ratio: 0 PB Ratio: 18.74 GF Score: 72/100

Q4 2018 Urogen Pharma Ltd Earnings Call Transcript

Feb 28, 2019 / 01:30PM GMT
Release Date Price: $38.48 (+0.26%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to UroGen Pharma's Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call. It is now my pleasure to turn the call over to Kate Bechtold, Director of Corporate Communications and Investor Relations for UroGen Pharma. Please go ahead.

Catherine Bechtold
UroGen Pharma Ltd. - Director of Corporate Communications & IR

Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter and full year ended December 31, 2018. The press release can be accessed on the Investors portion of our website at investors.urogen.com.

Joining me on the call today are Liz Barrett, President and Chief Executive officer; Dr. Mark Schoenberg, Chief Medical Officer; and Peter Pfreundschuh, Chief Financial Officer. Liz will provide

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot